Mainland China

Major Global Medical Device Manufacturer OrbusNeich Medical Group Announces Details of Proposed Listing on the Main Board of HKEX

Retrieved on: 
Tuesday, December 13, 2022
Marketing, Hong Kong Science Park, The Group, International, Growth, Percutaneous coronary intervention, NMPA, OrbusNeich, PTA, FDA, Hospital, Knowledge, Motherboard, Quality of life, D, Danna International (Offer Nissim Presents), NB, China International Capital Corporation, USD, PMDA, Mainland China, Patient, PCI, Physician, Neuro, CE marking, Stock exchange, HKEX, Headquarters, HK, Track record, BNP Paribas, Property management, Medical imaging, Fine chemical, Video game, Renewable energy, Medical device, Pharmaceutical industry, Oil, PRC, Limited

HONG KONG, Dec 13, 2022 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, has today announced the details of its proposed listing on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX").

Key Points: 
  • HONG KONG, Dec 13, 2022 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, has today announced the details of its proposed listing on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX").
  • In 2021, its global sales volume of PCI balloon products reached approximately 866,000 units
    -- A major PTA balloon developer and manufacturer in the global PTA balloons market, ranked No.
  • Dealing of the shares is expected to commence on the Main Board of HKEX on 23 December 2022 (Friday) under the stock code 6929.
  • OrbusNeich, headquartered in Hong Kong Science Park, is a major global medical device manufacturer specialized in interventional instruments for PCI and PTA procedures.

Investigation and analysis of the three major challenges and advantages of developing business in the GBA

Retrieved on: 
Tuesday, December 6, 2022
Internet, HKSAR, Research, Government, Hong Kong Export Credit Insurance Corporation, GDP, Hong Kong Trade Development Council, Risk management, GBA, Uncertainty, Mainland China, COVID-19, SME, Commissioner, City, Tutoring, Film, Road, Online shopping, Property management, Mainland, HKECIC, HKTDC

Riding on the development of the GBA, we will continue to support Hong Kong companies to seize the opportunities offered through the dual circulation strategy that can help them develop their business in the Mainland market."

Key Points: 
  • Riding on the development of the GBA, we will continue to support Hong Kong companies to seize the opportunities offered through the dual circulation strategy that can help them develop their business in the Mainland market."
  • There are also a number of Hong Kong companies which buy credit insurance (14.0%) either directly in Hong Kong or through banks in Hong Kong.
  • As such, Hong Kong companies should formulate the right business strategy targeting the domestic market as part of their plan to develop the GBA market.
  • The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the the Mainland and international markets.

AeroGuard Flight Training Center Signs Long Term Agreement With Cathay Pacific, Plans to Train Hundreds of Cadet Pilots at Its Phoenix, Arizona Campus

Retrieved on: 
Monday, December 5, 2022
Cathay Pacific, School, Weather, Student, Hong Kong Stock Exchange, Travel, Safety, Hong Kong Polytechnic University, Air Hong Kong, Swire, History, Aircraft, Burns, HK Express, House Subcommittee on Legislative Oversight, Immigration, Mainland China, Partnership, Airline, Tutoring, Aviation

Under these programs, Cathay Pacific plans to train over 1,000 cadet pilots by 2025, increasing capacity yearly to meet the growing travel demand expected within the premier Asian aviation hub.

Key Points: 
  • Under these programs, Cathay Pacific plans to train over 1,000 cadet pilots by 2025, increasing capacity yearly to meet the growing travel demand expected within the premier Asian aviation hub.
  • As the aviation industry rebounds across the globe following the pandemic, AeroGuard plans to train hundreds of future pilots for Cathay Pacific."
  • These new Cathay Pacific flight training programs are expected to take students approximately 10 months to complete with AeroGuard, taking students from no flight time to becoming a commercially rated pilot.
  • AeroGuard Flight Training Center is one of the U.S.'s most successful flight schools, offering accelerated commercial pilot training to candidates from all over the world.

Asia: Region of Opportunities

Retrieved on: 
Thursday, December 15, 2022
Biotechnology, Interview, Federal Reserve responses to the subprime crisis, Federal Reserve, COVID, Silverhorn, Uncertainty, AI, Policy, Government, VC, FAANG, Bank, Fine chemical, Risk management, Security (finance), Financial services, Mainland China

HONG KONG, Dec. 15, 2022 /PRNewswire/ -- In an interview with Marco Klaus, Silverhorn'sChief Investment Officer, Marco explains his view on public and private markets in anticipation of Silverhorn's annual outlook on Asia, the region of opportunities.

Key Points: 
  • HONG KONG, Dec. 15, 2022 /PRNewswire/ -- In an interview with Marco Klaus, Silverhorn'sChief Investment Officer, Marco explains his view on public and private markets in anticipation of Silverhorn's annual outlook on Asia, the region of opportunities.
  • This presents opportunities that Silverhorn as a fundamentally oriented asset manager can maximise.
  • In private markets, we see attractive investment opportunities in India and Southeast Asia, among others.
  • Accordingly, we spend plenty of time constructing robust portfolios to enhance long-term return opportunities.

The 23rd Hong Kong Forum gathered 100 global business leaders from Federation of Hong Kong Business Associations Worldwide to explore the latest opportunities in Hong Kong

Retrieved on: 
Thursday, December 1, 2022
Public affairs, Qatar Science & Technology Park, Sun Hung Kai, Forum, Hong Kong Trade Development Council, HKSTP, Communication, Li, M – Museum Leuven, West Kowloon Cultural District, HK, HKTDC, SME, Rosewood Hotel Group, GBA, Friends, Standard, Esquel Group, Guangdong-Hong Kong-Macau Greater Bay Area, Standard Chartered, Science, COVID-19, Hong Kong Science and Technology Parks Corporation, Senior advisor, HKSAR, Aviation, I&T, Culture, International airport, RCEP, Climate, Directorate of Research and Civil Affairs, Business, Business association, Federation, Tutoring, Management, Film, Research, Mainland China

The Forum, organised by the Hong Kong Trade Development Council (HKTDC), serves as the annual flagship event of the Federation of Hong Kong Business Associations Worldwide (FHKBAW).

Key Points: 
  • The Forum, organised by the Hong Kong Trade Development Council (HKTDC), serves as the annual flagship event of the Federation of Hong Kong Business Associations Worldwide (FHKBAW).
  • The two-day event, which concluded yesterday, welcomed more than 180 participants, including 100 global business leaders, in-person.
  • Mark Staublin, President of Hong Kong Business Association of the Midwest mentioned "This is my first visit to Hong Kong after two years.
  • With the help of the Hong Kong Trade Development Council (HKTDC), these Associations formed the Federation of Hong Kong Business Associations Worldwide in November 2000.

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

Retrieved on: 
Tuesday, November 29, 2022
Janus, COVID-19, JAK, Toxic Substances Control Act of 1976, Dermatology, Allergy, CMC, Therapy, Biotechnology, Patient, Neurology, Neonatology, Annual report, Medicine, Disease, Risk, ACRS, Atopic dermatitis, Pharmaceutical industry, Mainland China

Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris investigational soft Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan).

Key Points: 
  • Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris investigational soft Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan).
  • Under the terms of the agreement, Aclaris will receive an upfront payment of $5 million.
  • Aclaris is also eligible to receive a tiered royalty ranging from a low-to-high single digit percentage of net sales of ATI-1777 by Pediatrix in Greater China.
  • Pediatrix Therapeutics is a biotechnology company focusing on developing and commercializing high quality, pediatric-friendly and affordable therapeutics and healthcare products to children and families in China.

Regina Miracle Fiscal 2023 Interim Results Revenue Reaches HK$4.61 Billion; Hitting a Record High for the Period, Net Profit Rose 23.1% to HK$313 Million

Retrieved on: 
Tuesday, November 29, 2022
IDM, Growth, Waste management, EBITDA, Electronics, Fiscal, ESG, Intimate, Hand, Holding, R, GMV, Policy, Face, United Nations, Secrecy, Virtual reality, Industrial market segmentation, First Nations in Ontario, Plant, D11, Guangdong-Hong Kong-Macau Greater Bay Area, Tax, The Group, Agility, Tmall, Carbon, Social responsibility, Depreciation, Victoria's Secret, Public expenditure, Airline, Retail, Fine chemical, Marketing, Renewable energy, Hatmaking, PRC, Mainland China

Its total cash on hand was approximately HK$872.1 million as at 30 September 2022 (31 March 2022: approximately HK$995.0 million).

Key Points: 
  • Its total cash on hand was approximately HK$872.1 million as at 30 September 2022 (31 March 2022: approximately HK$995.0 million).
  • So that to enable Regina Miracle to grasp the opportunities for market penetration amid the industry consolidation."
  • This business segment contributed approximately HK$1,483.7 million in revenue during the Period (1HF2022: HK$1,036.4 million), a 43.2% year-on-year increase, accounting for 32.2% of total revenue.
  • Segmental gross profit was approximately HK$358.0 million and gross profit margin was 24.1% (1HF2022: HK$243.4 million and 23.5%, respectively).

Huobi and Dominica to Issue National Token DMC, Initiating the New Era of Digital Identity

Retrieved on: 
Tuesday, November 29, 2022
Technology, Finance, Banking, Professional Services, Metaverse, Software, Blockchain, Networks, Data Management, Cryptocurrency, TRON, Ethereum, Metaverse, Crypto, Growth, Inception, Digital, National Social Investment Program, United Kingdom, Union, Ambassador, Permanent, Digital identity, Partnership, Decentralization, Tourism, Lead, Era, DIDS, Baptist General Association of Virginia, DMC, Semantic Web, Commonwealth, KYC, DID, Cryptocurrency, Security (finance), Huobi, Mainland China

The three platforms were endorsed by the Dominica government to issue Dominica's national token, Dominica Coin (DMC), and Digital Identity (DID).

Key Points: 
  • The three platforms were endorsed by the Dominica government to issue Dominica's national token, Dominica Coin (DMC), and Digital Identity (DID).
  • Both issued by a sovereign country, DMC and DID are based on the TRON network, the official national blockchain infrastructure of Dominica, and are to be launched on Huobi Prime.
  • As a TRC-20 token authorized and issued by the Dominica government, DMC supports cross-chain interaction with Ethereum and BNB Smart Chain through the BTTC Bridge.
  • The tokens will be issued through Huobi Prime, and the platform will airdrop DMC and Dominica DIDs to all registered users.

Soundbite Medical Enters Into A License Agreement With VFLO Medical To Bring Its Products To Greater China

Retrieved on: 
Tuesday, November 15, 2022
Health, Medical Devices, Cardiology, Atherosclerosis, Prevalence, SBMS, Doctor of Philosophy, Agreement, Greater, Sound, Calcium, Patient, Pharmaceutical industry, Sound bite, Mainland China

Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that it has entered into an exclusive license agreement with VFLO Medical (VFLO).

Key Points: 
  • Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that it has entered into an exclusive license agreement with VFLO Medical (VFLO).
  • Pursuant to the agreement, Soundbite has granted VFLO an exclusive license for certain proprietary products including its SoundBite Crossing System and the Active Microcatheter System.
  • Under the Agreement, VFLO is entitled to manufacture, develop, and commercialize the products in the Greater China region, including Mainland China, Hong Kong, Macau, and Taiwan.
  • Soundbite is in return entitled to receive an upfront fee, subsequent milestone payments, plus royalties from sales of such products.

CICC UK Becomes the First Shanghai and Shenzhen Stock Exchanges-Approved German GDR Cross-Border Conversion Institution

Retrieved on: 
Thursday, November 17, 2022
SZSE, China International Capital Corporation, SIX Swiss Exchange, London Stock Exchange, Domestic, Professional, Global depository receipt, Supervision, Shenzhen Stock Exchange, Shanghai Stock Exchange, Mainland China, CICC, Frankfurt Stock Exchange, SSE, Research, Administration, FICC, FWB, Entrepreneurship, China Securities Regulatory Commission, LSE, SIX, Bank, Limited, GDR

BEIJING, Nov. 17, 2022 /PRNewswire/ --China International Capital Corporation Limited (CICC, 03908.HK, 601995.SH) announced that China International Capital Corporation (UK) Limited (CICC UK) has been approved by the Shanghai Stock Exchange (SSE) as a German Global Depositary Receipts (GDR) cross-border conversion institution under the stock connect schemes, in addition to SSE's previous approval of CICC UK as a UK and Swiss GDR cross-border conversion institution.

Key Points: 
  • BEIJING, Nov. 17, 2022 /PRNewswire/ --China International Capital Corporation Limited (CICC, 03908.HK, 601995.SH) announced that China International Capital Corporation (UK) Limited (CICC UK) has been approved by the Shanghai Stock Exchange (SSE) as a German Global Depositary Receipts (GDR) cross-border conversion institution under the stock connect schemes, in addition to SSE's previous approval of CICC UK as a UK and Swiss GDR cross-border conversion institution.
  • As a result, CICC UK has become the first and only GDR cross-border conversion institution approved by both the SSE and Shenzhen Stock Exchange (SZSE) for the German, UK and Swiss markets.
  • This was on the back of CICC UK recently becoming a member of the SIX Swiss Exchange (SIX) and the Frankfurt Stock Exchange (FWB) in addition to its membership of the London Stock Exchange (LSE).
  • CICC UK was established in 2009 and is regulated by the UK Financial Conduct Authority.